文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

溶瘤病毒治疗的发展：从基因修饰到联合治疗。

Development of oncolytic virotherapy: from genetic modification to combination therapy.

机构信息

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Fudan University, Shanghai, 200032, China.

Yantai Yuhuangding Hospital, Qingdao University, Yantai, 264000, China.

出版信息

Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.

DOI:10.1007/s11684-020-0750-4
PMID:32146606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7101593/
Abstract

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

摘要

溶瘤病毒治疗（OVT）是一种利用天然或基因改造病毒选择性在恶性肿瘤细胞中复制并杀死肿瘤细胞的新型免疫治疗方法。目前已经开发出许多具有增强肿瘤靶向性、抗肿瘤疗效和安全性的基因改造溶瘤病毒（OV），其中一些已经在临床试验中进行了评估。将 OVT 与其他免疫疗法相结合可以显著提高抗肿瘤疗效。在这项工作中，我们回顾了野生型病毒在 OVT 中的应用和 OV 基因改造的策略。我们还回顾和讨论了 OVT 与其他免疫疗法的联合应用。

相似文献

[1]
Development of oncolytic virotherapy: from genetic modification to combination therapy.

Front Med. 2020-3-7

[2]
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.

Front Immunol. 2021

[3]
Oncolytic viruses and their application to cancer immunotherapy.

Cancer Immunol Res. 2014-4

[4]
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.

J Transl Med. 2023-7-25

[5]
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.

Front Immunol. 2020

[6]
Oncolytic Virus-Driven Biotherapies from Bench to Bedside.

Small. 2023-6

[7]
Genetic modification of oncolytic viruses to enhance antitumor immunity.

Methods Enzymol. 2020

[8]
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.

J Immunother Cancer. 2021-1

[9]
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.

Clin Cancer Res. 2015-12-15

[10]
Application of oncolytic virus in tumor therapy.

J Med Virol. 2023-4

引用本文的文献

[1]
Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis.

EClinicalMedicine. 2025-7-19

[2]
Oncolytic Viruses as a Novel Therapeutic Approach for Colorectal Cancer: Mechanisms, Current Advances, and Future Directions.

Cancers (Basel). 2025-5-31

[3]
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.

Front Cell Dev Biol. 2025-2-3

[4]
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.

J Transl Med. 2024-11-5

[5]
Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges.

MedComm (2020). 2024-10-10

[6]
Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape.

World J Gastrointest Oncol. 2024-7-15

[7]
OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.

Int J Mol Sci. 2024-5-3

[8]
Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.

Int J Mol Sci. 2024-2-7

[9]
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.

Cancers (Basel). 2024-1-9

[10]
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.

Front Immunol. 2023

本文引用的文献

[1]
Tumour-intrinsic resistance to immune checkpoint blockade.

Nat Rev Immunol. 2019-9-30

[2]
Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.

Ann Surg Oncol. 2019-8-14

[3]
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.

BioDrugs. 2019-10

[4]
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.

Clin Cancer Res. 2019-7-4

[5]
A review of chimeric antigen receptor T-cells in lymphoma.

Expert Rev Hematol. 2019-6-19

[6]
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.

Nat Commun. 2019-5-28

[7]
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.

Mol Ther Oncolytics. 2019-3-27

[8]
Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.

Mol Ther Oncolytics. 2019-3-20

[9]
Poxvirus oncolytic virotherapy.

Expert Opin Biol Ther. 2019-4-4

[10]
Recombinant adenoviruses expressing apoptin suppress the growth of MCF‑7 breast cancer cells and affect cell autophagy.

Oncol Rep. 2019-3-18

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索